CCRAS transfers technology of Ayush-64 to 46 companies

Fresh license given to 39 companies for use in COVID-19

The Central Council for Research in Ayurvedic Sciences (CCRAS) has transferred the technology of herbal drug Ayush-64, effective in mild and asymptomatic and mild to moderate cases of COVID-19, to 46 companies.

Earlier only 7 companies including IMPCL, the manufacturing unit of the Ministry of Ayush, had its license, which used it for treatment of malaria. After being found effective on Corona during the COVID-19 outbreak, 39 new companies have been given fresh licenses i.e. technology has been transferred to them.

Ayush-64 has been developed by the CCRAS in 1980 for the treatment of malaria. During the first wave of COVID-19 in March 2020, some scientific studies found it to be very effective in mild and asymptomatic and mild to moderate infection of COVID-19. It also has properties of fighting viruses, increases body’s immunity and reduces fever, helping patients recover quickly.

During the first wave of COVID-19, a clinical trial was conducted with the Ministry of Ayush and the Council of Scientific and Industrial Research (CSIR), in which it was revealed that Ayush-64 is a very beneficial medicine for COVID-19 patients. So far, 8 clinical trials have been done on this, in which Ayush-64 was administered on 63 thousand patients quarantined at home, and the drug was found beneficial in this trial. There were also 5 random and two single studies in 8 clinical trials, where patients were given only Ayush-64 medicine.